PDF) Evaluation of the Relative Intranasal Abuse Potential of a Hydrocodone Extended-Release Tablet Formulated with Abuse-Deterrence Technology in Nondependent, Recreational Opioid Users
134 Improvements in Clinical Global Impression of Change With Deutetrabenazine Treatment in Tardive Dyskinesia From the ARM-TD a
UPDATE: N.J.'s $40M lures Teva HQ; Pa. refused to counter-offer
Teva Pharmaceuticals moving HQ to New Jersey – Daily Local